Managers / Q1 2019 · view latest →
Lion Point Capital, LP
CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200
Summary
Lion Point Capital, LP reported $1.1B in U.S.-listed holdings across 24 positions for Q1 2019.
Its largest position, LSCC, represents 8.5% of the portfolio.
Compared with Q4 2018, the fund opened 3 new positions and exited 12.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 50.0% · $553M
- ETP · 44.1% · $488M
- US DOMESTIC · 4.8% · $54M
- Other · 1.1% · $12M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2018 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PDCEUSDPDC ENERGY INC | NEW | +1.55M | 1.55M | +$63M | $63M |
| XLNXEURXILINX INC | NEW | +265.0K | 265.0K | +$34M | $34M |
| MDCOUSDMEDICINES CO | NEW | +150.0K | 150.0K | +$4M | $4M |
| ISHARES TR | ADDED | +2.83M | 2.83M | +$314M | $434M |
| SPDR SERIES TRUST | ADDED | +1.74M | 1.75M | +$25M | $54M |
| ARNCCHFARCONIC INC | ADDED | +954.8K | 1.35M | +$10M | $26M |
| ALDR1EURALDER BIOPHARMACEUTICALS INC | ADDED | +689.5K | 1.27M | +$11M | $17M |
| CRZOEURCARRIZO OIL & GAS INC | ADDED | +2.34M | 4.34M | +$32M | $54M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | LSCCLATTICE SEMICONDUCTOR CORPhistory → | COM | 8.47% | $94M | 7.86M |
| 2 | CSIQCANADIAN SOLAR INChistory → | COM | 7.81% | $86M | 4.64M |
| 3 | ALDR1EURALDER BIOPHARMACEUTICALS INC | NOTE 2.500% 2/0 · COM | 6.10% | $67M | 53.79M |
| 4 | PDCEUSDPDC ENERGY INChistory → | COM | 5.69% | $63M | 1.55M |
| 5 | CRZOEURCARRIZO OIL & GAS INChistory → | COM | 4.90% | $54M | 4.34M |
| 6 | AAALCOA CORPhistory → | COM | 3.64% | $40M | 1.43M |
| 7 | SCOR1EURCOMSCORE INChistory → | COM | 3.52% | $39M | 1.92M |
| 8 | ACHCACADIA HEALTHCARE COMPANY INhistory → | COM | 3.30% | $36M | 1.24M |
| 9 | ARNCCHFARCONIC INChistory → | COM | 2.33% | $26M | 1.35M |
| 10 | EQTEQT CORPhistory → | COM | 1.94% | $21M | 1.04M |
| 11 | FTSIEURFTS INTERNATIONAL INChistory → | COM | 1.50% | $17M | 1.66M |
| 12 | ENCANA CORP | COM | 0.98% | $11M | 1.50M |
| 13 | ZAYO GROUP HLDGS INC | COM | 0.72% | $8M | 282.0K |
| 14 | EXTREXTREME NETWORKS INC | COM | 0.55% | $6M | 811.8K |
| 15 | LOGCUSDLOGICBIO THERAPEUTICS INC | COM | 0.45% | $5M | 500.0K |
| 16 | MDCOUSDMEDICINES CO | COM | 0.38% | $4M | 150.0K |
| 17 | HORIZON PHARMA INVT LTD | NOTE 2.500% 3/1 | 0.31% | $3M | 3.00M |
| 18 | XPOXPO LOGISTICS INC | COM | 0.22% | $2M | 46.0K |
| 19 | OPES ACQUISITION CORP | UNIT 03/07/2023 | 0.08% | $865,000 | 83.4K |
| 20 | KEANE GROUP INC | COM | 0.00% | $43,000 | 4.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $17M | 35 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $19M | 39 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $18M | 27 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $15M | 19 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $16M | 21 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $19M | 19 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $45M | 25 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $55M | 27 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $179M | 32 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $200M | 30 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $224M | 31 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $221M | 30 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $243M | 31 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $703M | 32 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $454M | 41 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $878M | 40 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $431M | 35 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $373M | 33 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $533M | 38 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $579M | 34 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $550M | 30 | May 19, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2020 | $519M | 24 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $456M | 24 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $412M | 24 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $379M | 25 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.1B | 26 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $897M | 26 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.0B | 24 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.1B | 24 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $636M | 35 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.